Siemens’ X-Ray Eyes


Name Changes

Leaving Town


Corrections or additions?

This article by Barbara Fox was prepared for the May 29, 2002 edition of U.S. 1 Newspaper. All rights reserved.

Wireless R&D

The search for gene-based pain therapies at Purdue Pharma’s

new 115,000 square foot facility is being enhanced by a wireless network.

No matter where the researchers are working — at the lab bench

or in the cubicles — they can connect their laptops to the genome

sequences on the Internet and the company’s bioinformatics databases.

Tage Honore, head of Purdue Pharma’s new R&D group, says that though

his organization is entrepreneurial, it has deeper pockets than its

cohorts, so it has enough money for such "extras" as the wireless

network. "In our soul, we are like a biotech company but we have

a `big pharma’ economic structure," says Honore.

Honore, 51, was educated in Denmark, is married, and has two school-aged

children. Known for the discovery of the Ampa excitatory neuroreceptor,

Honore most recently directed research at Novartis in Switzerland.

When he came to head the R&D efforts at Purdue Pharma in October 2000,

60 people had already been hired. At 115,000 square feet in Cranbury,

he is hiring genomics, informatics, and proteomic scientists to raise

the head count from 110 to 140.

Commitment to computer technology is integral to Purdue Pharma, a

subsidiary of Purdue Frederick, a privately owned company funded in

large part by the Sackler family. The fact that, early in the history

of the Web, the company plucked a plum website name —

— would bear this out. "You can guess the family applied for

that name very early in the Internet story," says Honore.

The ownes are committed to developing new medicine for pain. "We

put two new potential drug candidates in the pipeline in the first

year, and they have very competitive profiles. One is a broad spectrum

sodium channel blocker for pain, and the other is a neuro steroid

for insomnia," says Honore.

Purdue Pharma LP, 6 Cedar Brook Drive, Cedar Brook

Corporate Center, Cranbury 08512. Tage Honore, vice president of discovery

research. 609-409-5123; fax, 609-409-5799. Home page:

Top Of Page
Siemens’ X-Ray Eyes

Seven centimeters is a long way for your scalpel to

cut if you are cutting into someone’s brain to find a tumor. You hope

you know precisely where that tumor is. As it turns out, the ability

to conjure up three-dimensional pictures of someone’s anatomy can

be the difference between a good surgeon and a great surgeon. A great

surgeon "sees" what is below any surface in a three-dimensional


Until now, surgeons have had to look at a scan of a tumor on a light

screen, put it together with their minds’ eye views of an anatomical

model, and then try to imagine where that tumor is. But a new Siemens

technology can essentially render the patient transparent to the surgeon.

This "in-situ visualization," a kind of augmented reality

(AR), lets the surgeon see a tumor in three-dimensional space from

different angles, says Frank Sauer, a project manager at Siemens Corporate

Research on College Road. He received his undergraduate degree in

Stuttgart and has a PhD in optical information technology from the

University of Erlangen, and has been working at Siemens for 10 years.

"The ability to look inside the patient and see the tumor in three-dimensional

space from different angles helps the surgeon determine the best route

to the tumor," says Sauer. His prototype — discussed 10 years

ago but made possible now by faster computers — uses a head-mounted

display with three miniature cameras. Two of them take a stereoscopic

(3D) view of the surgical site, and the third is used for viewpoint

tracking, so that no matter which way the head is angled, the user

sees the correct view. "We want the surgeon to have direct access

to this information and make it available in context with the patient’s

body," says Sauer. A metal "halo" helps to keep everything

in synch.

Pre-clinical tests on "phantom" objects have been performed,

and results are encouraging. Clinical testing could begin by the end

of 2002.

Siemens Corporate Research Inc. (SI), 755 College

Road, Forrestal Center, Princeton 08540. Norbert Gaus, CEO. 609-734-6500;

fax, 609-734-6565.

Top Of Page

J. Kerney Kuser II, Attorney (), 230 Nassau Street,

Princeton 08542. 609-921-0888; fax, 609-921-6442.

J. Kerney Kuser II has expanded to 1,000 square feet with a move from

1 Palmer Square to 230 Nassau Stret. A graduate of Kenyon College

and the Seton Hall School of Law, he specializes in real estate, trusts

and estates, and corporate law. His great grandfather had owned the

Trenton Times.

Top Of Page
Name Changes

Griswold Special Care, 14 Washington Road, Building

6, Suite 615, Princeton 08540. Joseph (Mandella, director. 609-799-8856.

Home page:

To honor the founder of this 20-year-old company, Jean Griswold of

Erdenheim, Pennsylvania, the nursing service provider has changed

its name from Special Care to Griswold Special Care. It has more than

70 offices in 12 states, and there is a Middlesex County office at

732-745-7788. The company offers caregivers for a wide range of conditions

on an hourly, overnight, or live-in basis.

Top Of Page
Leaving Town

BostonCoach, 780 Dowd, Elizabeth. Ronn Harris,

site supervisor. 908-965-0056 or 800-672-7676; fax, 908-965-1596.

Home page:

Boston Coach, a limousine firm, has closed its office at Research

Park (19 Wall Street) and is planning to move it to Bridgewater, but

in the meantime is operating out of the New York area headquarters

in Elizabeth. Three years ago it had started a satellite branch here

with a fleet of 25 Volvos.

Top Of Page

Irving Flicker, 87, on May 27. He was chairman emeritus

of Homasote Company on Lower Ferry Road.

Next Story

Corrections or additions?

This page is published by

— the web site for U.S. 1 Newspaper in Princeton, New Jersey.

Facebook Comments